摘要
目的:观察新辅助化疗对中期宫颈癌的疗效。方法106例中期宫颈癌患者按照数字表法随机分为观察组和对照组,各53例。观察组在手术前采用紫杉醇与顺铂( TP)方案新辅助化疗,对照组直接行手术治疗。观察化疗总有效率和化疗前后肿瘤直径变化,并测定观察组血清血管内皮生长因子( VEGF)和基质金属蛋白酶9(MMP-9)的变化,同时比较两组手术情况。结果化疗结束后观察组总有效率为60.4%;化疗前后观察组肿瘤平均直径分别为(5.24±1.35) cm、(2.64±0.67) cm,差异有统计学意义( t=3.947,P<0.05)。在手术时间、术中出血量及淋巴结转移方面,观察组均明显优于对照组( t=3.725、5.392,χ2=4.28, P<0.05或P<0.01)。观察组患者化疗后血清VEGF和MMP-9均比化疗前有明显降低( t=3.130、4.724,均P<0.05)。结论新辅助化疗可以明显降低中期宫颈癌患者血清VEGF和MMP-9的表达。
Objective To observe the effect of neoadjuvant chemotherapy for patients with advanced cervical cancer.Methods According to the digital table ,106 patients with advanced cervical cancer were randomly divided into the two groups ,53 cases in each group .The observation group was given TP Scheme neoadjuvant chemotherapy before surgery ,the control group underwent surgery directly .The total effective rate of chemotherapy and the changes of diameter of tumor before and after chemotherapy were observed .The serum levels of vascular endothelial growth fac-tor(VEGF) and matrix metalloproteinase-9(MMP-9) of the observation group were detected ,and the operation condi-tions were compared between the two groups .Results After chemotherapy ,the total effective rate of the observation group was 60.4%.Before and after chemotherapy ,the average tumor diameter of the observation group was (5.24 ± 1.35)cm,(2.64 ±0.67)cm,respectively,the difference was significant (t=3.947,P〈0.05).The operative time, blood loss and lymph node metastasis in the observation group were significantly less than those in the control group (t=3.725,5.392,χ2 =4.28,P〈0.05 or P〈0.01).After chemotherapy,the serum levels of VEGF and MMP-9 were significantly lower than that before chemotherapy (t=3.130,4.724,all P〈0.05).Conclusion Neoadjuvant chemotherapy in the treatment of advanced cervical cancer can significantly reduce serum VEGF and MMP-9 expression.
出处
《中国基层医药》
CAS
2014年第19期2929-2931,共3页
Chinese Journal of Primary Medicine and Pharmacy
关键词
宫颈肿瘤
抗肿瘤联合化疗方案
血管内皮生长因子
基质金属蛋白酶9
Uterine cervical neoplasms
Antineoplastic combined chemotherapy protocols
Vascular endothe-lial growth factors
Matrix metalloproteinase 9